Prospects for an SV40 vaccine.
The identification of SV40 as a possible cause of human cancer leads to the question of whether the unique properties of the virus can be exploited to treat patients with SV40-positive mesotheliomas, which are otherwise refractory to successful intervention. A modified SV40 T antigen, from which the transforming domains have been removed, has been cloned into a vaccinia virus vector and tested in animal tumor model systems. It has been shown to be effective against both subsequent tumor challenge and pre-existing tumors. Thus, the potential exists for use of such a vaccine in mesothelioma patients.
Department of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor 48109-0942, USA. imperial@umich.edu
M J
MJ
Imperiale
H I
HI
Pass
M G
MG
Sanda
D006801:Humans; D016233:Immunotherapy, Active; D008654:Mesothelioma / Q000628:therapy* / Q000821:virology; D030361:Papillomavirus Infections / Q000628:therapy* / Q000821:virology; D013539:Simian virus 40 / Q000276:immunology*; D014412:Tumor Virus Infections / Q000628:therapy* / Q000821:virology; D014765:Viral Vaccines / Q000627:therapeutic use*
D014765:Viral Vaccines